Vcanbio Cell & Gene Engineering Corp Debt/EBITDA
The Total Debt to EBITDA Ratio of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Oct 9, 2026 is 0.30. In the previous year, Total Debt to EBITDA Ratio was 0.53 — a change of -43.60% (lower).
Get this data via API
Financial Data API
Debt/EBITDA
0.30
YoY
-43.60%
Last updated:
The Vcanbio Cell & Gene Engineering Corp Debt/EBITDA history
3 Years
10 Years
25 Years
Max
| YEAR | Debt/EBITDA | YoY |
|---|---|---|
| 0.30 | -43.60% | |
| 0.53 | -1.92% | |
| 0.54 | +89.46% | |
| 0.28 | -104.92% | |
| -5.76 | -850.16% | |
| 0.77 | -56.37% | |
| 1.76 | +27.95% | |
| 1.38 | +28.03% | |
| 1.07 | +502.30% | |
| 0.18 | — |
Vcanbio Cell & Gene Engineering Corp Stock analysis
Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock
Total Debt to EBITDA Ratio of Vcanbio Cell & Gene Engineering Corp is 0.30 in 2024.
Total Debt to EBITDA Ratio of Vcanbio Cell & Gene Engineering Corp changed from 0.53 to 0.30, representing a -43.60% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.
Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Vcanbio Cell & Gene Engineering Corp with sector peers and the industry average to assess whether it is attractive.
Leverage — Vcanbio Cell & Gene Engineering Corp
All Key Metrics — Vcanbio Cell & Gene Engineering Corp
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth